BCX 1470

Serine protease inhibitor CAS# 217099-43-9

BCX 1470

Catalog No. BCC1413----Order now to get a substantial discount!

Product Name & Size Price Stock
BCX 1470: 5mg $207 In Stock
BCX 1470: 10mg Please Inquire In Stock
BCX 1470: 20mg Please Inquire Please Inquire
BCX 1470: 50mg Please Inquire Please Inquire
BCX 1470: 100mg Please Inquire Please Inquire
BCX 1470: 200mg Please Inquire Please Inquire
BCX 1470: 500mg Please Inquire Please Inquire
BCX 1470: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of BCX 1470

Number of papers citing our products

Chemical structure

BCX 1470

3D structure

Chemical Properties of BCX 1470

Cas No. 217099-43-9 SDF Download SDF
PubChem ID 9822205 Appearance Powder
Formula C14H10N2O2S2 M.Wt 302.38
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Thrombin inhibitor
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name (2-carbamimidoyl-1-benzothiophen-6-yl) thiophene-2-carboxylate
SMILES C1=CSC(=C1)C(=O)OC2=CC3=C(C=C2)C=C(S3)C(=N)N
Standard InChIKey OTGQTQBPQCRNRG-UHFFFAOYSA-N
Standard InChI InChI=1S/C14H10N2O2S2/c15-13(16)12-6-8-3-4-9(7-11(8)20-12)18-14(17)10-2-1-5-19-10/h1-7H,(H3,15,16)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of BCX 1470

DescriptionBCX 1470 inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin. IC50 Value: 96 nM (Factor D); 1.6 nM (C1s); 326 nM (Trypsin) [1] Target: Factor D; C1s BCX 1470(Thrombin inhibitor) is serine protease inhibitor.BCX 1470(Thrombin inhibitor) blocks the esterolytic and hemolytic activities of the complement enzymes Cls and factor D in vitro, also blocked development of RPA-induced edema in the rat.

References:
[1]. Szalai, Alexander J.; Digerness, Stanley B.; et al.; The Arthus Reaction in Rodents: Species-Specific Requirement of ComplementJournal of Immunology, 2000, 164, 463-468

BCX 1470 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

BCX 1470 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of BCX 1470

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.3071 mL 16.5355 mL 33.071 mL 66.1419 mL 82.6774 mL
5 mM 0.6614 mL 3.3071 mL 6.6142 mL 13.2284 mL 16.5355 mL
10 mM 0.3307 mL 1.6535 mL 3.3071 mL 6.6142 mL 8.2677 mL
50 mM 0.0661 mL 0.3307 mL 0.6614 mL 1.3228 mL 1.6535 mL
100 mM 0.0331 mL 0.1654 mL 0.3307 mL 0.6614 mL 0.8268 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on BCX 1470

IC50: FD 96 nM, C1 1.6 nM
C1s is an 80-kDa serine protease that mediates the proteolytic activity of the C1 complex by cleaving C2 and C4 both. BCX-1470, discovered in 1997 as a FD inhibitor (IC50=96 nM), was further found to be a very potent C1s inhibitor (IC50=1.6 nM).
In vitro: BCX-1470 has the highest inhibitory activity of Factor D, with an IC50 of approx. 100 nM, which is two orders higher than the inhibitory activity of another commercially available general protease inhibitor, named FUT-175, when inhibting FD [1].
In vivo: BCX-1470 has been shown to be safe in animal toxicity studies and has blocked the development of reverse-passive Arthus reactioninduced oedema in rats [1].
Clinical trial: BCX-1470 has also been tested for safety in clinical trials with healthy volunteers but the outcome of these trials have not officially been published. Whereas no further clinical trials have been reported, a recent patent might indicate a future usage of the compound in the treatment of AMD. It suggests that BCX-1470 would be a candidate therapeutic for complement activation during cardiopulmonary bypass surgery
Reference:
[1] Morikis D, Lambris JD. Structural aspects and design of low-molecular-mass complement inhibitors. Biochem Soc Trans. 2002;30(Pt 6):1026-36.

Featured Products
New Products
 

References on BCX 1470

The Arthus reaction in rodents: species-specific requirement of complement.[Pubmed:10605043]

J Immunol. 2000 Jan 1;164(1):463-8.

We induced reverse passive Arthus (RPA) reactions in the skin of rodents and found that the contribution of complement to immune complex-mediated inflammation is species specific. Complement was found to be necessary in rats and guinea pigs but not in C57BL/6J mice. In rats, within 4 h after initiation of an RPA reaction, serum alternative pathway hemolytic titers decreased significantly below basal levels, whereas classical pathway titers were unchanged. Thus the dermal reaction proceeds coincident with systemic activation of complement. The serine protease inhibitor BCX 1470, which blocks the esterolytic and hemolytic activities of the complement enzymes Cls and factor D in vitro, also blocked development of RPA-induced edema in the rat. These data support the proposal that complement-mediated processes are of major importance in the Arthus reaction in rats and guinea pigs, and suggest that BCX 1470 will be useful as an anti-inflammatory agent in diseases where complement activation is known to be detrimental.

Description

BCX 1470 inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.

Keywords:

BCX 1470,217099-43-9,Thrombin inhibitor,Natural Products,Serine Protease, buy BCX 1470 , BCX 1470 supplier , purchase BCX 1470 , BCX 1470 cost , BCX 1470 manufacturer , order BCX 1470 , high purity BCX 1470

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: